CHAMPAIGN, Ill. — Flightpath Biosciences, Inc., a clinical stage biotechnology company focused on the development of precision therapeutics targeting bacterial pathogens, has licensed a class of antibiotics developed at the University of Illinois Urbana-Champaign. The original antibiotic agent, lolamicin, effectively treated bacterial infections in animal models of disease — without wiping out beneficial microbes in the gut. The Illinois team is continuing to develop derivatives of lolami...
